Apollomics, Inc. (NASDAQ:APLM – Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 10,800 shares, a decline of 50.5% from the December 15th total of 21,800 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 309,200 shares, the days-to-cover ratio is currently 0.0 days.
Apollomics Stock Up 2.9 %
APLM opened at $10.85 on Tuesday. Apollomics has a 52 week low of $6.50 and a 52 week high of $105.00. The business has a 50 day moving average price of $10.33 and a two-hundred day moving average price of $13.63.
Institutional Investors Weigh In On Apollomics
An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC raised its holdings in Apollomics, Inc. (NASDAQ:APLM – Free Report) by 247.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned 1.41% of Apollomics worth $179,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.13% of the company’s stock.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Further Reading
- Five stocks we like better than Apollomics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- What PMI Data Says About the NFP Report: 3 Hidden Opportunities
- Airline Stocks – Top Airline Stocks to Buy Now
- Cintas: Trade Uncertainty Creates a Buy-the-Dip Opportunity
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Stocks to Benefit From China’s Rare Earth Export Ban on U.S.
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
